EGFR and non-small cell lung carcinoma: In addition, a phase II study suggested synergistic activity in first-line treatment with a combination of bevacizumab and erlotinib in stage IIIb/IV NSCLC [17], and the addition of bevacizumab to erlotinib has been reported to prolong PFS in patients with NSCLC with activating EGFR mutations compared with erlotinib alone [18].